These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32896803)

  • 41. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia.
    Glynn P; Coakley R; Kilgallen I; Murphy N; O'Neill S
    Thorax; 1999 Jan; 54(1):51-5. PubMed ID: 10343632
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency department.
    Fiumefreddo R; Zaborsky R; Haeuptle J; Christ-Crain M; Trampuz A; Steffen I; Frei R; Müller B; Schuetz P
    BMC Pulm Med; 2009 Jan; 9():4. PubMed ID: 19152698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Admission Pentraxin-3 Level Predicts Severity of Community-Acquired Pneumonia Independently of Etiology.
    Luo Q; He X; Ning P; Zheng Y; Yang D; Xu Y; Shang Y; Gao Z
    Proteomics Clin Appl; 2019 Jul; 13(4):e1800117. PubMed ID: 30557448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission.
    Scicluna BP; Klein Klouwenberg PM; van Vught LA; Wiewel MA; Ong DS; Zwinderman AH; Franitza M; Toliat MR; Nürnberg P; Hoogendijk AJ; Horn J; Cremer OL; Schultz MJ; Bonten MJ; van der Poll T
    Am J Respir Crit Care Med; 2015 Oct; 192(7):826-35. PubMed ID: 26121490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity.
    Salluh JIF; Bozza FA; Soares M; Verdeal JCR; Castro-Faria-Neto HC; Lapa E Silva JR; Bozza PT
    Chest; 2008 Nov; 134(5):947-954. PubMed ID: 18753464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response.
    Tejera A; Santolaria F; Diez ML; Alemán-Valls MR; González-Reimers E; Martínez-Riera A; Milena-Abril A
    Cytokine; 2007 Jun; 38(3):117-23. PubMed ID: 17659879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic cytokines and chemokines on admission of children hospitalized with community-acquired pneumonia.
    Vasconcellos ÂG; Clarêncio J; Andrade D; Cardoso MA; Barral A; Nascimento-Carvalho CM
    Cytokine; 2018 Jul; 107():1-8. PubMed ID: 29158121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic profiles in community-acquired pneumonia: developing assessment tools for disease severity.
    Ning P; Zheng Y; Luo Q; Liu X; Kang Y; Zhang Y; Zhang R; Xu Y; Yang D; Xi W; Wang K; Chen Y; An S; Gao Z
    Crit Care; 2018 May; 22(1):130. PubMed ID: 29759075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endogenous carboxyhemoglobin concentrations in the assessment of severity in patients with community-acquired pneumonia.
    Corbacioglu SK; Kilicaslan I; Bildik F; Guleryuz A; Bekgoz B; Ozel A; Keles A; Demircan A
    Am J Emerg Med; 2013 Mar; 31(3):520-3. PubMed ID: 23219346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.
    Yende S; D'Angelo G; Kellum JA; Weissfeld L; Fine J; Welch RD; Kong L; Carter M; Angus DC;
    Am J Respir Crit Care Med; 2008 Jun; 177(11):1242-7. PubMed ID: 18369199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia.
    Ramírez P; Ferrer M; Martí V; Reyes S; Martínez R; Menéndez R; Ewig S; Torres A
    Crit Care Med; 2011 Oct; 39(10):2211-7. PubMed ID: 21705887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Coagulopathy correlates with outcomes in patients with community- acquired pneumonia].
    Zhuang Q; Zeng Y; Shi Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):406-10. PubMed ID: 25200038
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic value of blood parameters for community-acquired pneumonia.
    Huang Y; Liu A; Liang L; Jiang J; Luo H; Deng W; Lin G; Wu M; Li T; Jiang Y
    Int Immunopharmacol; 2018 Nov; 64():10-15. PubMed ID: 30144639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Usefulness of plasma YKL-40 in management of community-acquired pneumonia severity in patients.
    Wang HL; Hsiao PC; Tsai HT; Yeh CB; Yang SF
    Int J Mol Sci; 2013 Nov; 14(11):22817-25. PubMed ID: 24256818
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.
    Kellum JA; Kong L; Fink MP; Weissfeld LA; Yealy DM; Pinsky MR; Fine J; Krichevsky A; Delude RL; Angus DC;
    Arch Intern Med; 2007 Aug 13-27; 167(15):1655-63. PubMed ID: 17698689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).
    Kuzman I; Bezlepko A; Kondova Topuzovska I; Rókusz L; Iudina L; Marschall HP; Petri T
    BMC Pulm Med; 2014 Jun; 14():105. PubMed ID: 24975809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot Study.
    Arnold FW; Bordon J; Fernandez-Botran R; Rane MJ; Uriarte SM; Kelley R; Wiemken TL; Peyrani P; Ramirez JA;
    Lung; 2016 Feb; 194(1):155-62. PubMed ID: 26553025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia.
    Kao SJ; Yang HW; Tsao SM; Cheng CW; Bien MY; Yu MC; Bai KJ; Yang SF; Chien MH
    Clin Chem Lab Med; 2013 Apr; 51(4):907-13. PubMed ID: 23152412
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia.
    de Brito RC; Lucena-Silva N; Torres LC; Luna CF; Correia JB; da Silva GA
    BMC Pulm Med; 2016 Dec; 16(1):170. PubMed ID: 27905908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome.
    Chien JY; Hsueh PR; Cheng WC; Yu CJ; Yang PC
    Respirology; 2006 Nov; 11(6):715-22. PubMed ID: 17052299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.